NCT07146815View on ClinicalTrials.gov

PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease

NACompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions
NAFLD (Nonalcoholic Fatty Liver Disease)Polycystic Ovarian Syndrome (PCOS)
Interventions
DIAGNOSTIC_TEST

FibroScan

Performance of a FibroScan measurement to determine the prevalence of liver steatosis.

DIAGNOSTIC_TEST

MRI PDFF

Performance of an MRI-PDFF to determine amount of liver steatosis.

Trial Locations (1)

3600

Ziekenhuis Oost-Limburg, Genk

All Listed Sponsors
lead

Ziekenhuis Oost-Limburg

OTHER